These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 3613164)

  • 21. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)].
    Koitabashi Y; Maruyama T; Ikoma M; Miyaji Y; Yamada K; Shimizu K
    Rinsho Ketsueki; 1982 Mar; 23(3):309-18. PubMed ID: 7050462
    [No Abstract]   [Full Text] [Related]  

  • 23. Can thrombolytics prevent post-phlebitic syndrome and thrombo-embolic disease?
    Trübestein G
    Haemostasis; 1986; 16 Suppl 3():38-50. PubMed ID: 3770543
    [No Abstract]   [Full Text] [Related]  

  • 24. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
    Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of fibrinolytic system, especially that of alpha 2 plasmin inhibitor deficient patient.
    Sakata Y
    Nihon Ketsueki Gakkai Zasshi; 1981 Dec; 44(7):1506-12. PubMed ID: 7342652
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):86-8. PubMed ID: 8756739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
    Páramo JA; Collen D
    Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
    [No Abstract]   [Full Text] [Related]  

  • 32. Cyclic variation of plasminogen activation in human uterine fluid and the influence of an intrauterine device.
    Casslén B; Ohlsson K
    Acta Obstet Gynecol Scand; 1981; 60(2):97-101. PubMed ID: 6454324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biological profile of the 1st 4 hours of a thrombolytic treatment combining urokinase with lysyl-plasminogen].
    Roncato M; Vitoux JF; Pernes JM; Aiach M; Fiessinger JN; Gaux JC; Housset E; Leclerc M
    Ann Biol Clin (Paris); 1985; 43(6):851-5. PubMed ID: 3832977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
    D'Angelo A; Mannucci PM
    Thromb Haemost; 1984 Apr; 51(2):236-9. PubMed ID: 6740556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and secretion of the fibrinolytic components, including alpha 2-antiplasmin, by a human hepatoma cell line.
    Fair DS; Plow EF
    J Lab Clin Med; 1983 Mar; 101(3):372-84. PubMed ID: 6186756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant correlation between the immunofluorescence of alpha 2-plasmin inhibitor in glomeruli and the effects of urokinase therapy in patients with IgA nephropathy.
    Miura M; Tomino Y; Yagame M; Inoue W; Suga T; Nomoto Y; Sakai H
    Ann Acad Med Singap; 1986 Apr; 15(2):255-7. PubMed ID: 3530107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of venous stasis on plasminogen activation and plasma alpha 2-antiplasmin levels in type II diabetes mellitus].
    Longoni P; Montani N; Gangale MG; Gamba G
    Recenti Prog Med; 1987; 78(7-8):323-7. PubMed ID: 3423401
    [No Abstract]   [Full Text] [Related]  

  • 40. alpha 2-plasmin inhibitor levels in relation to modes of urokinase administration.
    Matsuo O; Kosugi T; Mihara H; Ohki Y; Matsuo T
    Thromb Res; 1980 Jul 1-15; 19(1-2):271-5. PubMed ID: 6449754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.